Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited, have announced that the first patient has been treated with CYP-001, the Company’s first mesenchymal stem cell (MSC) product, in its Phase I clinical trial.
Commenting on the news, Keith Thompson, CEO, Cell and Gene Therapy Catapult said,
It is fantastic news that Cynata Therapeutics have commenced treatment of patients with their iPSC derived mesenchymal stem cell (MSC) product, CYP-001, in a clinical trial for the treatment of steroid resistant acute graft-versus-host disease (GvHD).
This trial is a world first using MSCs derived from iPSC’s, for which Prof. Yamanaka of Japan won a Nobel prize. The fact that Cynata Therapeutics have selected the UK as one of the locations for this trial is a testament to the supportive regulatory environment and clinical infrastructure here in the UK.
Read the full press release here.